SAN DIEGO, June 9 /PRNewswire-FirstCall/ -- Bioscientia, a leading international reference laboratory will participate as a European site for a joint working group on molecular diagnostics initiated by SEQUENOM, Inc. and Siemens Medical Solutions of Siemens AG . SEQUENOM's MassARRAY(R) Compact System, a genetics analysis platform, will be installed at Bioscientia's clinical reference laboratory facility in Germany to benchmark the MassARRAY System in a molecular diagnostic testing environment.
This collaboration combines the specialized assets and resources of the three organizations. Siemens Medical Solutions, a world leader in medical instrumentation and medical information technology, will contribute project funding and engineering expertise and Bioscientia, a leading molecular genetic analysis provider, will perform the study. SEQUENOM will provide its MassARRAY Compact, consumables, technical support and analytically validated assays for specific tests, including deep vein thrombosis and HIV.
In late 2004, Siemens and SEQUENOM had announced their partnership to work in concert with participating reference laboratories to execute a comprehensive functional requirement analysis for a molecular diagnostics platform. Bioscientia joins U.S. based Specialty Laboratories as an integral part of the joint working group.
The first phase of the joint program is a benchmarking study evaluating the analytical data quality and current workflow of the MassARRAY System in clinical reference laboratories. SEQUENOM expects the benchmarking study to be completed by the fourth quarter 2005.
"One of the goals of the joint working group is to evaluate the utility of mass spectrometry through benchmarking studies," said Mohammad Naraghi, M.D., Ph.D., Senior Vice President of Business Development at Siemens. "Bioscientia has a state-of-the-art molecular genetics analysis laboratory and brings more than 25 years of clinical diagnostic experience to the team. Their global client base and breadth of their experience will be a major asset."
"We are enthusiastic about working with Siemens, who is truly on the forefront in developing next-generation molecular diagnostic applications. We believe this field will continue to grow as the number of genetically defined diseases increases," stated Priz. Doz. med. Markus Nauck, Chief Executive Officer and Chief Financial Officer of Bioscientia. "We anticipate assessing the utility of the MassARRAY Compact for a range of standard and challenging applications in the benchmarking study with Siemens."
"The initial study results from Specialty Laboratories in the U.S. are positive; demonstrating the ease of use, speed and multiplexing capabilities of our MassARRAY system. So far, we have achieved 100% concordance with current diagnostic testing modalities," stated Harry Stylli, President and Chief Executive Officer of SEQUENOM. "The inclusion of Bioscientia in the joint working group should provide the important exposure in the international molecular genetic analysis market. We anticipate that a successful outcome from the benchmarking study should position the MassARRAY system as a leading universal platform for molecular diagnostics due to its sensitivity, accuracy and flexibility."
Bioscientia, based in Ingelheim, Germany, is an international reference laboratory founded in 1970. Today, it is one of the largest purpose built reference laboratories in Europe with a staff in excess of 900 professional and technical personnel. With more than 25 years experience in the international market, Bioscientia provides a pathology reference service to a wide range of institutions including universities, military, and Ministry of Health hospitals, clinics, laboratories and pharmaceutical companies world wide. For more information, please visit Bioscientia's website at http://www.bioscientia.de/englisch/frame-eng.htm.
About Siemens Medical Solutions
Siemens Medical Solutions of Siemens AG , with headquarters in Malvern, PA and Erlangen, Germany, is one of the largest suppliers to the healthcare industry in the world. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable clinical and financial outcomes. Employing approximately 31,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.07 billion EUR, orders of 8.12 billion EUR and group profit of 1.05 billion EUR for fiscal 2004. More information can be obtained by visiting http://www.usa.siemens.com/medical-pressroom.
SEQUENOM is committed to providing the best genetic analysis products that translate genomic science into superior solutions for molecular medicine and biomedical research. The Company's proprietary MassARRAY System is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. For more information on SEQUENOM, please visit our website at www.sequenom.com.
SEQUENOM(R) and MassARRAY(R) are registered trademarks of SEQUENOM, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements concerning the goals of the joint working group and benchmarking study, the expected completion of the benchmarking study by the fourth quarter of 2005, the results thereof, related plans and activities described herein, next-generation molecular diagnostics applications, the anticipation that a successful outcome from the benchmarking study should position the MassARRAY system as a leading universal platform for molecular diagnostics, and statements including the words "will" "expect" "anticipate" or "should," are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the development, benchmarking, and commercialization of any new technology, including SEQUENOM's technologies, and other risks detailed from time to time in SEQUENOM's SEC filings, including SEQUENOM's Annual Report on Form 10-K for the year ended December 31, 2004, and most recently Quarterly Report on Form 10-Q. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO
AP Archive: http://photoarchive.ap.org